Search Results

• • 39 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.

  Authors:Jay H. Shubrook, Michael Radin, Sarah N. Ali, Barrie Chubb, Kristina DiPietrantonio, Hannah Collings, et al.From:Advances in Therapy (Vol. 39, Issue 9) Peer-Reviewed

  Sept. 2022314 words Report, Brief articl...

   Abstract Only

• How well are we managing diabetes in long-term care? The care received by nursing home residents with diabetes does not meet ADA standards for ambulatory adults, this study finds. Nor should it. The frail elderly need new standards that address their particular needs

  Authors:Brittney M. Vajen, Tracy Marx, Frank L. Schwartz, and Jay H. Shubrook, Jr.From:Journal of Family Practice (Vol. 61, Issue 8) Peer-Reviewed

  Aug. 20123,209 words Report 1510LABSTRACT Purpose Our objective was to compare the management of diabetes mellitus (DM) in residents of extended-care facilities with the American Diabetes Association (ADA) standards of care for ambulatory adults....

• Evolution of Type 2 Diabetes Treatment.

  Authors:Jay H. Shubrook and Kim PfotenhauerFrom:Journal of Family Practice (Vol. 69, Issue 10) Peer-Reviewed

  Dec. 20206,087 words Medical procedure ov... 2240LINTRODUCTION Primary care professionals deal with many patients with many diseases, including individual patients who may have multiple chronic diseases. One such chronic disease is type 2 diabetes (T2D), the most...

• What we know--and don't--about non-nutritive sweeteners: Here's what's known about the safety of these sweeteners and their effect on weight, appetite, and the risk for type 2 diabetes

  Authors:Joy Dugan, Jeff W. Chiu, Jay H. Shubrook, and Clipper F. YoungFrom:Journal of Family Practice (Vol. 68, Issue 6) Peer-Reviewed

  July-August 20193,782 words Article 2120LAn estimated 93.3 million Americans (roughly 40% of the US population) were obese in 2015-2016, and most of them had at least 1 chronic disease. (1) As a result, patient education focused on lifestyle modification,...

• Lifetime duration of depressive disorders in patients with type 2 diabetes

  Authors:Mary de Groot, Kent A. Crick, Molly Long, Chandan Saha, and Jay H. ShubrookFrom:Diabetes Care (Vol. 39, Issue 12) Peer-Reviewed

  Dec. 2016 Report

   Citation Only

• Insulin for type 2 diabetes: how and when to get started: with guidelines now calling for initiation of basal insulin for patients who are not at goal a year after diagnosis, familiarity with optimal timing, dosing, and titration is critical for family physicians

  Author:Jay H. ShubrookFrom:Journal of Family Practice (Vol. 63, Issue 2) Peer-Reviewed

  Feb. 20143,156 words Report 1600LWith type 2 diabetes now affecting 8.3% of the US population, most primary care physicians see patients with this disorder every day) Based on the concurrent obesity epidemic, aging population, and emergence of type 2...

• Intensive insulin therapy as the primary treatment for type 2 diabetes

  Authors:Lubaina S. Presswala and Jay H. ShubrookFrom:Clinical Diabetes (Vol. 29, Issue 4) Peer-Reviewed

  Fall 20111,533 words Article 1540LPresentation A 47-year-old obese, white man with a history of prediabetes and dyslipidemia presented to his primary care physician for a routine follow-up. He weighed 285.6 lb, and his BMI was 39.8 kg/[m.sup.2]. He...

• Advances in Type 2 Diabetes: Focus on Basal Insulin/ Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy

  Author:Jay H. ShubrookFrom:Journal of Family Practice (Vol. 67, Issue 8) Peer-Reviewed

  Aug. 20185,630 words Report 1790LINTRODUCTION Despite a greater understanding of pathophysiologic processes of type 2 diabetes mellitus (T2DM) and new classes of medications targeting these processes, the treatment of persons with T2DM remains a...

• Reducing CV risk in diabetes: an ADA update

  Authors:Neil Skolnik, Florence M. Jaffa, Rita R. Kalyani, Eric Johnson, and Jay H. ShubrookFrom:Journal of Family Practice (Vol. 66, Issue 5) Peer-Reviewed

  May 20175,495 words Report 1800LThis Q&A highlights changes to the ADA's 2017 Standards of Care to help you fine-tune your approach to patients who have, or are at risk for, atherosclerotic CV disease. More than 29 million Americans have diabetes,...

• Correlations Between A1C and Diabetes Knowledge, Diabetes Numeracy, and Food Security in a Vulnerable Type 2 Diabetes Population

  Authors:Clipper F. Young, Kenneth Yun, Edward Kang, Jay H. Shubrook, and Joy A. DuganFrom:Diabetes Spectrum (Vol. 31, Issue 2) Peer-Reviewed

  Spring 2018 Article

   Citation Only

• Diabetes update: your guide to the latest ADA standards: the authors highlight the latest changes in the ADA standards and review recommendations of particular relevance for family physicians

  Authors:Eric Johnson, Florence Warren, Neil Skolnik, and Jay H. ShubrookFrom:Journal of Family Practice (Vol. 65, Issue 5) Peer-Reviewed

  May 20165,057 words Report 1470LPrevention of diabetes, as well as early detection and treatment of both prediabetes and diabetes, is critical to the health of our country. Because evidence-based guidelines are key to our ability to effectively...

• Cost-effectiveness of Community-Based Depression Interventions for Rural and Urban Adults With Type 2 Diabetes: Projections From Program ACTIVE (Adults Coming Together to Increase Vital Exercise) II.

  Authors:Shihchen Kuo, Wen Ye, Mary de Groot, Chandan Saha, Jay H. Shubrook, W. Guyton Hornsby, Jr., et al.From:Diabetes Care (Vol. 44, Issue 4) Peer-Reviewed

  Apr. 2021 Report

   Citation Only

• Impact of activity participation and depression on glycemic control in older adults with diabetes: glycemic control in nursing homes

  Authors:Julie L. Bellissimo, Rachel M. Holt, Stephanie M. Maus, Tracy L. Marx, Frank L. Schwartz, and Jay H. ShubrookFrom:Clinical Diabetes (Vol. 29, Issue 4) Peer-Reviewed

  Fall 20113,292 words Report 1540LIn the United States, 23.1% of adults [greater than or equal to] 60 years of age have diabetes. (1) This population is also burdened with an increased cumulative risk of multiple complications. (2) The risk of these...

• Diabetes numeracy and blood glucose control: association with type of diabetes and source of care

  Authors:Stephanie D. Zaugg, Godwin Dogbey, Karen Collins, Sharon Reynolds, Carter Batista, Grace Brannan, et al.From:Clinical Diabetes (Vol. 32, Issue 4) Peer-Reviewed

  Fall 2014 Report

   Citation Only

• Advances in Type 2 Diabetes: Focus on Basal Insulin/ Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy

  Author:Jay H. ShubrookFrom:Clinician Reviews (Vol. 28, Issue 6) Peer-Reviewed

  July-August 20185,612 words Report 1780LINTRODUCTION Despite a greater understanding of pathophysiologic processes of type 2 diabetes mellitus (T2DM) and new classes of medications targeting these processes, the treatment of persons with T2DM remains a...

• Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study

  Authors:Ildiko Lingvay, Andreas R. Kirk, Søren Lophaven, Michael L. Wolden, and Jay H. ShubrookFrom:Diabetes Therapy (Vol. 12, Issue 3) Peer-Reviewed

  Mar. 20216,616 words Report 1520LIntroduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are highly effective for glycaemic control and weight loss in patients with type 2 diabetes (T2D). In this retrospective, observational study, we...

• Preparing for the NASH Epidemic: A Call to Action.

  Authors:Fasiha Kanwal, Jay H. Shubrook, Zobair Younossi, Yamini Natarajan, Elisabetta Bugianesi, Mary E. Rinella, et al.From:Diabetes Care (Vol. 44, Issue 9) Peer-Reviewed

  Sept. 2021 Report

   Citation Only

• Empagliflozin in the treatment of type 2 diabetes: evidence to date

  Authors:Jay H. Shubrook, Babak Baradar Bokaie, and Sarah E. AdkinsFrom:Drug Design, Development and Therapy (Vol. 9) Peer-Reviewed

  Annual 20156,353 words Report 1760LIn the last decade, researchers have gained a greater understanding of the pathophysiologic mechanisms of type 2 diabetes as a chronic and progressive disease. One of the more recent treatment targets is the kidney. The...

• The Time Is Now: Diabetes Fellowships in the United States

  Authors:Archana R. Sadhu, Amber M. Healy, Shivajirao P. Patil, Doyle M. Cummings, Jay H. Shubrook, and Robert J. TanenbergFrom:Current Diabetes Reports (Vol. 17, Issue 11)

  Nov. 2017417 words Report

   Abstract Only

• Program ACTIVE II: Outcomes From a Randomized, Multistate Community-Based Depression Treatment for Rural and Urban Adults With Type 2 Diabetes

  Authors:Mary de Groot, Jay H. Shubrook, W. Guyton Hornsby, Yegan Pillay, Kieren J. Mather, Karen Fitzpatrick, et al.From:Diabetes Care (Vol. 37, Issue 6) Peer-Reviewed

  June 2014 Report

   Citation Only